6-cyclohexyl-4-methyl-5-{4-[2-morpholino-5-(2-oxopyrrolidin-1-yl)benzyloxy]phenyl}-4H-thieno[3,2-b]pyrrole-2-carboxylic acid hydrochloride | 852699-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 6-cyclohexyl-4-methyl-5-{4-[2-morpholino-5-(2-oxopyrrolidin-1-yl)benzyloxy]phenyl}-4H-thieno[3,2-b]pyrrole-2-carboxylic acid hydrochloride
• 英文别名: 6-Cyclohexyl-4-methyl-5-[4-[[2-morpholin-4-yl-5-(2-oxopyrrolidin-1-yl)phenyl]methoxy]phenyl]thieno[3,2-b]pyrrole-2-carboxylic acid;hydrochloride
• CAS: 852699-70-8
• 化学式: C₃₅H₃₉N₃O₅S*ClH
• 分子量: 650.239
• InChiKey: VARJLNIAXNWIDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.62
• 重原子数：
  45
• 可旋转键数：
  8
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20090036444A1

  公开（公告）日：2009-02-05

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性具有抗HCV活性，是一种预防或治疗丙型肝炎的药剂。
• 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Mizojiri Ryo

  公开号：US20120020920A1

  公开（公告）日：2012-01-26

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]所表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明化合物基于HCV聚合酶抑制活性具有抗HCV活性，可用作预防或治疗丙型肝炎的药剂。